Understanding and targeting cancer stem cells: therapeutic implications and challenges
Top Cited Papers
Open Access
- 20 May 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Acta Pharmacologica Sinica
- Vol. 34 (6), 732-740
- https://doi.org/10.1038/aps.2013.27
Abstract
Cancer stem cells (CSCs) have been identified as rare cell populations in many cancers, including leukemia and solid tumors. Accumulating evidence has suggested that CSCs are capable of self-renewal and differentiation into various types of cancer cells. Aberrant regulation of gene expression and some signaling pathways has been observed in CSCs compared to other tumor cells. CSCs are thought to be responsible for cancer initiation, progression, metastasis, recurrence and drug resistance. The CSC hypothesis has recently attracted much attention due to the potential for discovery and development of CSC-related therapies and the identification of key molecules involved in controlling the unique properties of CSC populations. Over the past several years, a tremendous amount of effort has been invested in the development of new drugs, such as nanomedicines, that can take advantage of the “Achilles' heel” of CSCs by targeting cell-surface molecular markers or various signaling pathways. Novel compounds and therapeutic strategies that selectively target CSCs have been identified, some of which have been evaluated in preclinical and clinical studies. In this article, we review new findings related to the investigation of the CSC hypothesis, and discuss the crucial pathways involved in regulating the development of CSC populations and the advances in studies of drug resistance. In addition, we review new CSC-targeted therapeutic strategies aiming to eradicate malignancies.Keywords
This publication has 101 references indexed in Scilit:
- Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: A systematic reviewDrug Resistance Updates, 2011
- Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistanceDrug Resistance Updates, 2010
- Immunity, Inflammation, and CancerCell, 2010
- Tumor heterogeneity: Causes and consequencesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2010
- Co‐delivery of Doxorubicin and Bcl‐2 siRNA by Mesoporous Silica Nanoparticles Enhances the Efficacy of Chemotherapy in Multidrug‐Resistant Cancer CellsSmall, 2009
- Therapeutic targeting of microenvironmental interactions in leukemia: Mechanisms and approachesDrug Resistance Updates, 2009
- Cancer stem cells: Cell culture, markers, and targets for new therapiesJournal of Cellular Biochemistry, 2009
- Super pH-sensitive multifunctional polymeric micelle for tumor pHe specific TAT exposure and multidrug resistanceJournal of Controlled Release, 2008
- Expansion of liver cancer stem cells during aging in methionine adenosyltransferase 1A-deficient miceJournal of Hepatology, 2007
- HEDGEHOG-GLI1 Signaling Regulates Human Glioma Growth, Cancer Stem Cell Self-Renewal, and TumorigenicityCurrent Biology, 2007